Galvani Bioelectronics
 | |
| Company type | Subsidiary |
|---|---|
| Industry | Bioelectronics |
| Founded | November 2016[1] |
| Founders | [2] |
| Headquarters | , |
Key people | Kristoffer Famm (President)[4] |
| Parent | GlaxoSmithKline (55% equity interest)[3] |
| Website | galvani |
Galvani Bioelectronics is a United Kingdom-based bioelectronics R&D company founded by Alphabet Inc. subsidiary Verily Life Sciences and British pharmaceutical company GlaxoSmithKline (GSK) in November 2016.[1][2] The partnership to form the company was announced on 1 August 2016.[3]
Verily has a 45% equity interest while GSK has a 55% equity interest, making GSK the effective owner.[3] The initial agreed upon investment between the two companies is up to £540 million over a period of seven years.[3] Additionally, both companies agreed to contribute their existing intellectual property rights.
The company is based in Stevenage.[5]
External links
References
- ^ a b c "Galvani Bioelectronics Website". Galvani Bioelectronics. Retrieved 24 December 2016.
- ^ a b "Galvani Bioelectronics". Verily Life Sciences website. Retrieved 24 December 2016.
- ^ a b c d e Temperton, James (1 August 2016). "GSK and Google just created a £540m bioelectronic health firm". Wired (website). Retrieved 24 December 2016.
- ^ "Kristoffer Famm Ph.D. - Galvani Bioelectronics". Galvani Bioelectronics. Retrieved 25 December 2016.
- ^ Kollewe, Julia (2017-08-28). "Electroceuticals: the 'bonkers' gamble that could pay off for GlaxoSmithKline". the Guardian. Retrieved 2018-08-03.
 | This article about a company of the UK is a stub. You can help Wikipedia by expanding it. |